What Is Olezarsen?
Olezarsen is a drug currently being investigated in clinical trials. It is designed to be administered as a subcutaneous (SC) injection, meaning it is given under the skin. As of the latest data, 10 clinical trials have been conducted or are underway, involving a total of 3,834 participants. The first trial began on September 29, 2020, with the latest starting on April 11, 2024. Olezarsen is primarily being studied for its potential to manage conditions characterized by high levels of triglycerides, a type of fat in the blood. These conditions include familial chylomicronemia syndrome, severe hypertriglyceridemia, and general hypertriglyceridemia. Additionally, researchers are exploring its potential benefits in cardiovascular diseases and atherosclerosis, conditions often associated with elevated lipid levels. Ionis Pharmaceuticals, Inc. is sponsoring all current research into Olezarsen.
Uses and Conditions Under Study
Olezarsen is currently being investigated in several clinical trials for its potential to treat conditions related to high levels of fats in the blood and their associated complications.
- High Triglyceride Disorders: Olezarsen is being studied for its effects on conditions characterized by very high levels of triglycerides, a type of fat in the blood.
- Familial Chylomicronemia Syndrome (FCS): This is a rare genetic disorder where the body cannot break down certain fats, leading to extremely high triglyceride levels and a risk of pancreatitis. Olezarsen is being investigated in 4 trials for FCS.
- Severe Hypertriglyceridemia: This refers to dangerously high triglyceride levels that can lead to health problems like pancreatitis. Olezarsen is being evaluated in 4 trials for this condition.
- Hypertriglyceridemia: This is a more general term for elevated triglycerides. Olezarsen is being studied in 2 trials to assess its broader impact on reducing these fat levels.
- Cardiovascular and Atherosclerotic Diseases: High triglyceride levels are a known risk factor for various heart and blood vessel conditions.
- Cardiovascular Diseases: Olezarsen is being explored in 1 trial for its potential role in managing broader cardiovascular health.
- Atherosclerosis and Atherosclerotic Cardiovascular Disease: These conditions involve the hardening and narrowing of arteries due to plaque buildup, often exacerbated by high lipid levels. Olezarsen is being investigated in 1 trial for atherosclerosis and 1 trial for atherosclerotic cardiovascular disease, suggesting a focus on preventing or managing the progression of these conditions.
- Healthy Participants: One trial involving healthy participants is typically conducted to understand how the drug is absorbed, distributed, metabolized, and excreted by the body, as well as to assess its safety profile in individuals without the target condition. This helps inform appropriate dosing and potential side effects when the drug is used in patients.
Dosing
Olezarsen is administered as a subcutaneous (SC) injection, meaning it is given under the skin. In clinical trials, various investigational dosage forms and strengths of Olezarsen have been studied to determine the most effective and safest treatment regimens.
The specific dosage forms investigated include:
- Olezarsen
- Olezarsen Dose Level 1
- Olezarsen Dose Level 2
These "Dose Level" designations suggest that researchers are exploring different quantities or concentrations of the drug to find the optimal therapeutic effect.
Additionally, specific strengths of Olezarsen have been studied:
- Olezarsen 50 mg
- Olezarsen 80 mg
These strengths are being evaluated across the various conditions Olezarsen is being investigated for, including familial chylomicronemia syndrome and severe hypertriglyceridemia. The goal of these dosing studies is to establish a clear understanding of how different amounts of Olezarsen impact triglyceride levels and overall patient outcomes, while also monitoring for any potential side effects. The exact frequency of administration (e.g., once daily, weekly, or monthly) would be determined based on the results of these trials and the drug's pharmacokinetic profile.
Side Effects
In a clinical trial involving patients with familial chylomicronemia syndrome (FCS), the most commonly reported side effects for Olezarsen included pain in the extremities, headache, and abdominal pain. The trial included 43 patients who received Olezarsen and a placebo group for comparison.
- Pain in extremity was reported by 11.6% of patients taking Olezarsen, compared to 4.3% of patients on placebo.
- Headache occurred in 11.6% of patients receiving Olezarsen, while 13.0% of patients on placebo experienced headaches.
- Abdominal pain was reported by 16.3% of patients on Olezarsen, which was lower than the 34.8% reported by patients on placebo.
- Arthralgia (joint pain) was experienced by 9.3% of Olezarsen patients, compared to 0.0% on placebo.
- Platelet count decreased in 9.3% of patients taking Olezarsen, versus 4.3% on placebo.
- Urinary tract infection occurred in 9.3% of Olezarsen patients, compared to 0.0% on placebo.
- Injection site pain was reported by 7.0% of patients receiving Olezarsen, while 0.0% of patients on placebo experienced it.
- Anxiety was reported by 7.0% of patients on Olezarsen, compared to 0.0% on placebo.
Clinical Trial Results
Clinical trials have investigated the effectiveness of Olezarsen in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely high triglyceride levels and a high risk of acute pancreatitis. The primary study, NCT04568434, evaluated Olezarsen's impact on acute pancreatitis events and various lipid markers.
Reduction in Acute Pancreatitis Events
Olezarsen significantly reduced the rate of acute pancreatitis events. Over the entire treatment period (Week 1 through Week 53):
- The mean rate of acute pancreatitis events was 4.37 events per 100 participant-years for patients on Olezarsen, compared to 36.31 events per 100 participant-years for those on placebo.
- For patients with a prior history of pancreatitis, the mean event rate was 6.73 events per 100 participant-years with Olezarsen, versus 66.22 events per 100 participant-years with placebo.
- In patients who had experienced two or more pancreatitis events in the five years before enrollment, Olezarsen reduced the mean event rate to 16.59 events per 100 participant-years, compared to 118.59 events per 100 participant-years for placebo.
Improvements in Lipid Markers
Olezarsen also demonstrated improvements in key lipid markers associated with FCS, with higher doses generally showing greater effects. Lower values for these markers typically indicate better control of the condition.
- Fasting Apolipoprotein C-III (apoC-III): This protein is a direct target of Olezarsen. At Month 12, patients receiving Olezarsen 80 mg experienced a 66.13% reduction in apoC-III from baseline, while those on Olezarsen 50 mg saw a 57.91% reduction. In contrast, placebo patients experienced a 7.57% increase.
- Fasting Triglycerides (TG): At Month 12, patients on Olezarsen 80 mg had a 38.50% reduction in fasting triglycerides, and those on Olezarsen 50 mg had a 22.92% reduction. Placebo patients, however, saw their fasting triglycerides increase by 20.89%. At Month 6, 40.9% of patients on Olezarsen 80 mg achieved a 40% or greater reduction in fasting triglycerides, compared to 4.3% on placebo.
- Fasting Apolipoprotein B-48 (apoB-48): At Month 12, Olezarsen 80 mg led to a 79.15% reduction in apoB-48, while Olezarsen 50 mg resulted in an 8.78% reduction. Placebo patients experienced a 3.52% reduction.
- Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): At Month 12, patients on Olezarsen 80 mg showed a 27.69% reduction in Non-HDL-C, and those on Olezarsen 50 mg had a 17.84% reduction. Placebo patients experienced a 12.01% increase.